L Montus Abl Tablet SR is a combination medication containing Ambroxol 75mg, Levocetirizine 5mg, and Montelukast 10mg, formulated to provide comprehensive management of respiratory conditions characterized by cough, allergic rhinitis, and bronchial asthma. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of mucus from the respiratory tract, thereby improving airway patency and easing expectoration. Levocetirizine, a potent second-generation antihistamine, selectively inhibits peripheral H1 receptors, effectively reducing symptoms of allergic rhinitis such as sneezing, nasal congestion, and itching without causing significant sedation. Montelukast, a leukotriene receptor antagonist, blocks leukotriene D4 at the cysteinyl leukotriene receptor, mitigating bronchoconstriction, inflammation, and edema associated with asthma and allergic rhinitis. The sustained-release formulation ensures prolonged therapeutic action, enhancing patient compliance by reducing dosing frequency. L Montus Abl Tablet SR is indicated for the symptomatic relief and management of chronic respiratory conditions involving mucus hypersecretion, allergic manifestations, and bronchospasm. It should be used under medical supervision, especially in patients with hepatic impairment or hypersensitivity to any components. Common adverse effects may include headache, gastrointestinal discomfort, and mild sedation. This combination offers a multi-targeted approach to respiratory care, optimizing symptom control and improving quality of life.